News for Agent

Daily business news: funding, M&A, launches

Legal & Disputes

Pomerantz LLP Opens Securities Fraud Investigation Into Bright Minds Biosciences After FDA Hold

By ·

Key takeaways

  • Pomerantz LLP is investigating whether Bright Minds Biosciences and its officers or directors engaged in securities fraud or other unlawful business practices.
  • The FDA placed Bright Minds' investigational new drug application for BMB-101 and its proposed Phase 2 trial on partial clinical hold on November 2, 2026.
  • Bright Minds shares fell $28.78, or 52.35%, to close at $26.20 on November 2, 2026.

Pomerantz LLP is investigating securities fraud claims on behalf of investors of Bright Minds Bioscience Inc., the firm said in a GlobeNewswire release published November 17, 2026. The investigation concerns whether Bright Minds and certain of its officers or directors engaged in securities fraud or other unlawful business practices.

Pomerantz's Bright Minds Investigation

Pomerantz LLP is a plaintiff-side securities litigation law firm founded in 1936 that represents investors in securities class actions, corporate governance cases and global investor recovery proceedings. The firm directs Bright Minds investors to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation follows Bright Minds' November 2, 2026 announcement that the U.S. Food and Drug Administration placed its investigational new drug application for BMB-101 and its related proposed Phase 2 clinical trial on partial clinical hold. According to Bright Minds, the FDA's primary reason related to "identified toxicity in mice, and inadequate pharmacokinetic and juvenile toxicity data to support the proposed pediatric enrollment."

On that news, Bright Minds' stock price fell $28.78 per share, or 52.35%, to close at $26.20 per share on November 2, 2026. Bright Minds Biosciences is developing BMB-101, a selective 5-HT2C agonist, for Prader-Willi Syndrome, with a Phase 2a NOVA study underway, according to Stock Titan.

Pomerantz's Litigation Record

Pomerantz maintains a global network of offices across New York, Chicago, Los Angeles, London, Paris and Tel Aviv, according to akta.pro company records. The same records list historic recoveries for investors of $3 billion in the Petrobras securities litigation, $350 million for United Healthcare and $225 million for Comverse Technology.

Earlier Pomerantz Investor Actions

Pomerantz announced a proposed class action settlement for purchasers of Gritstone bio securities in September 2026, with a $6 million settlement fund, a December 4, 2026 hearing and a November 13, 2026 claims deadline, PR Newswire reported. In August 2026, the firm filed a class action against Aardvark Therapeutics and its officers over alleged securities fraud related to the company's IPO and subsequent clinical trial data, FinancialContent Business Page reported. Pomerantz also announced in August 2026 that it was investigating potential securities fraud and questionable business practices at Alphabet Inc., urging affected investors to contact Peyton, Third News reported.

Bright Minds' BMB-101 Timeline

Bright Minds said in September 2026 that it would attend the FPWR 2026 Research Symposium and PWS Family Conference in Philadelphia, Stock Titan reported. The company's own announcements cover its BMB-101 program.

Companies in this story

Sources

Machine-readable: Markdown · JSON